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ISSUE BRIEF/No. 762
State-Based Pharmaceutical
Assistance Programs
The rallying cry for a Medicare outpatient prescrip-
tion drug benefit reached a fevered crescendo in the
2000 presidential and statewide elections. Despite the
furor and the consensus in Congress that something
needed to happen, however, agreement on the shape of
a federally mandated Medicare drug benefit failed to
emerge. Early this year, President Bush announced
guidelines for his Immediate Helping Hand Program
—an interim Medicare prescription drug assistance
program that most observers have concluded was
“dead on arrival.” So the states, as they have done in
the past, continue to take action. Now, however, the
number of states involved has grown and their ap-
proaches to the programs have diversified. Going
beyond the traditional assistance programs, states are
trying their hands at group purchasing, price controls,
and discount programs.
Over the past two years, more than one-half of the
states have established some type of prescription drug
assistance program for the elderly. While some of
these state programs are more robust than others, they
all seek to help meet a particularly difficult challenge
—providing prescription drug coverage for Medicare
beneficiaries.
The desire to establish such a benefit is not new.
Ever since 1969, efforts have been under way to pro-
vide this benefit for Medicare beneficiaries. However,
while interest has ebbed and flowed over the years,
federal legislators have yet to enact such a provision. In
the meantime, others have been trying to pick up the
slack: the pharmaceutical industry through its patient
assistance programs; the private marketplace through
retiree health benefits, Medigap policies, and Medicare
risk plans; and the states through Medicaid1 and state
pharmaceutical assistance programs.
As prescription medications have comprised an
increasing portion of the expenditures for health care,
federal interest in enacting a Medicare outpatient
prescription drug benefit has come once again to the
fore. Politically, the stakes are high; a mid-term election
is just around the corner. Consensus on how best to
proceed appears to be elusive, however. Most of the
current federal proposals fall into four general catego-
ries: (a) a stand-alone Medicare drug benefit, (b)
insurance approaches with premium support, (c) price
controls, and (d) state block-grant programs. It is likely
that each one of these would affect the various state-
based programs differently.
While the states keep one eye focused on Washing-
ton, D.C., they must keep the other on their own
capitols and pocketbooks. States are finding it harder
than ever to provide pharmaceutical assistance—the
economy is slowing, Medicaid budgets, including
prescription drug line items are exploding, and some
Medicare health maintenance organizations that
provide prescription drug coverage are pulling out of
selected markets.
In a February 8, 2001, article, “Slowing Economy
Forces Governors to Trim Budgets,” the New York
Times reported that,
with a swiftness that has taken many governors by
surprise, the slowing economy has sharply reduced
state tax revenues in the last few weeks, forcing a
growing number of states around the South and
Midwest to cut their budgets for the first time in a
decade. . . . Coming at the same time as a steep in-
crease in Medicaid costs, the budget reversals mean
that the days of bold new programs and tax cuts are
over in many states.
What does this portend for the state pharmaceutical
assistance programs? Even with reserve funds that
states have accumulated, rising prescription drug costs,
increasing numbers of elderly patients, and decreasing
state tax revenues spell danger for these programs.
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STATE PHARMACY PROGRAMS:
FACTS AND FIGURES
As of January 2001, 26 states had authorized some
type of pharmaceutical assistance program. States have
been creating such programs for low-income elderly or
disabled persons since 1975. According to a report issued
in September 2000 by the U.S. General Accounting
Office (GAO), in 1999, 14 states operated 18 state-funded
pharmacy assistance programs serving more than 760,000
enrollees.2 While New Jersey, New York, and Pennsylva-
nia enrolled the most people overall in their programs that
year and accounted for 71 percent of all enrollees, the
Rhode Island program enrolled the largest percentage of
Medicare beneficiaries in the state.
Drug assistance programs span a wide range in their
benefit design, eligibility requirements, funding mecha-
nisms, and cost controls. According to the National
Conference on State Legislatures (NCSL):
 Twenty-two states have enacted laws to create pro-
grams; four other programs have been created by
executive branch action only.
 Twenty-four state programs are in operation3; an
enacted law in Kansas and an agency program in
Iowa are not yet in operation.
 Twenty states provide a direct subsidy using state
funds; Missouri provides a subsidy only by a year-
end tax credit.
 Five additional states (California, New Hampshire,
Iowa, Washington, and West Virginia) have recently
created programs that offer a discount only (no
subsidy) for eligible or enrolled seniors.
In summing up last year’s frenzied activity in the
states, the NCSL’s February 9, 2001, report, Prescrip-
tion Drug Discount, Rebate, Price Control and Bulk
Purchasing Legislation, 1999-2000, indicated that
some states have adjusted eligibility for Medicaid,
with its prescription benefit, to cover additional
people. A relatively new trend focuses on statewide
programs aimed at achieving substantially lower
pharmaceutical prices for broader categories of
consumers. Generally these bills seek to use
Medicaid-style rebates, other discount rates or current
‘lowest available price’ as a basis for a retail price,
instead of providing a direct state-funded subsidy. A
new law in Maine and proposals in several additional
states also called for state price controls that would
apply to public consumer purchases.
Table 1 (see page 4) summarizes much of the past
year’s nontraditional prescription assistance program
activities undertaken by states.
STATE RX PROGRAM PARAMETERS
While no two state programs are alike, they all must
deal with similar issues of design, administration, and
funding. As states begin the very difficult task of
bringing new programs to life, officials look to veteran
programs for lessons learned. Although there is much to
share, each state must still consider its own set of
circumstances. Each state has a unique elderly (and/or
disabled) population distribution (that is, percentage of
low-income, percentage with retiree health benefits that
covers prescription drugs) a unique set of economic
considerations, a unique market environment (that is,
number, if any, of Medicare risk plans), and a unique
political apparatus.
The challenge for states, of course, is to provide a
pharmacy assistance benefit to a targeted population
while keeping within budget (which, by way of compar-
ison, is very small relative to state Medicaid budgets).
All states must consider the following as they began to
build their programs4:
 Eligibility criteria (age and income).
 Cost-sharing/cost management arrangements.
 Program administration/delivery systems.
 Marketing and outreach.
 Funding.
Eligibility Criteria
The biggest determinants of program eligibility are
age and income. Drug assistance programs typically are
targeted towards the elderly (65 years of age and older)
and the disabled. Income limits (which are distin-
guished between individual limits and married or
household limits) vary, for instance, from 100 percent
to well over 200 percent of the federal poverty level for
a single person.5 In order not to exclude individuals,
some states allow income limit exceptions for people
with drug expenditures exceeding a certain percentage
of their income. Income thresholds are generally
adjusted each year to account for cost-of-living adjust-
ments to Social Security income. For some programs,
however, the Social Security cost-of-living adjustment
issue has been problematic in that beneficiaries have
had to leave the program.
Cost-Sharing–Cost-Management
Arrangements
Plans use several methods to manage costs and
utilization. The most common are copayments and
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Table 1
Prescription Drug Discount, Rebate, Price Control, and Bulk Purchasing Legislation
1999–2000
Description of Policy for Prescription Drugs States with Bills or Laws, 1999-2000
Medicare elders/disabled eligible for discount prices
based on Medicaid rates
AZ, CA, CT, CO, FL, MA, MD, ME, MN, MO,
NH, OH, RI, VT, WA, WI
Seniors eligible for discount prices based on
Federal Supply Schedule
AZ, IL, PA, VT
Broader public use of federally qualified health centers
(FQHCs obtain prescription drugs at discounts similar to
the best Medicaid rebate rates)
CT, RI, VT
State bulk purchasing to achieve greater price discounts
for all eligible groups
AZ, CA, FL, MA, ME, NH, NY, OR, RI, VT, WA
State “buyer’s clubs” (nonlegislative, via governors’
offices)
IA, ME, NH, VT, WA, WV
(executive initiatives)
State coordination of pharmaceutical industry free/
charity programs
MA, NH
Advertising costs disclosed to the state PA
Price controls or state maximum prices   AZ, CA, CT, ME, MI, NJ, NY, OH, PA, VT
Source: National Conference of State Legislatures, Prescription Drug Discount, Rebate, Price Control and Bulk Purchasing
Legislation, 1999-2000, 2; accessed February 9, 2001, at http://www.ncsl.org/programs/health/drugdisc.htm.
coinsurance, both a form of beneficiary cost-sharing. The
level of cost-sharing, however, varies from plan to plan,
and is different for brand and generic drug products.
Some programs use benefit caps (usually annual caps),
premium payment, and enrollment fees. Again, there is
wide variation across programs. Almost all the state
prescription drug assistance programs rely on manufac-
turer rebates (typically calculated on terms similar to
Medicaid rebates) to offset costs. Other cost management
methods employed by some programs include limiting the
number of prescriptions per month, limiting the supply
dispensed, covering drugs for certain conditions only,
covering only maintenance drugs, and using mail order
services. Very few states use deductibles and most
programs offer first-dollar coverage.
The GAO study notes that, unlike private insurance,
state-run drug assistance programs “generally do not
use formularies to limit coverage to specific products
within a given therapeutic class.” However, as men-
tioned above, some states do restrict coverage to
particular types of drugs (that is, maintenance drugs or
drugs to treat specific conditions.)
Program Administration-Delivery Systems
One particularly challenging issue facing program
administrators involves encouraging program participa-
tion while increasing efficiencies, given the limited
resources typically available for state assistance pre-
scription drug programs. Just as it has plagued other
assistance programs for other populations, the stigma or
perceived stigma affiliated with a low-income program,
has been, according to some plan administrators, a
deterrent to beneficiary enrollment. According to the
GAO study,
Program administrators in some states said that their
legislature created drug assistance programs that are
administered separately from Medicaid to avoid any
association with such perceived stigma. An official in
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one state said that the drug assistance program is
regarded favorably by the public because it is distinct
from the Medicaid program.
The trade-off is that, in administering two separate
programs—Medicaid and a distinct state assistance
prescription drug program—economies of scale are lost.
This is particularly troublesome where duplicative
program functions, such as eligibility determination, the
processing and payment of claims, and coordination of
benefit payment when a beneficiary has other drug
coverage, could be avoided.
On the other hand, states have been creative. Some
have run the prescription drug assistance program as a
separate program but have tapped in to their Medicaid
administrative systems, while others have linked with
different state senior assistance programs, most notably
rent or property tax assistance. Many of the agency
administrators report using contractors to assist with
program functions, particularly in the cases of eligibility
determination and claims processing.
Marketing and Outreach
In addition to the stigma problem, administrators
have found potential beneficiaries to be unaware of the
program. In order to create increased awareness, some
plans have undertaken outreach programs, designed to
bolster participation.
Funding and Budget Levels
Budget levels for the state prescription drug pro-
grams vary, but all are small, relative to state Medicaid
programs. Most are funded by legislative appropriations
from states’ general revenues and others are funded by
lottery funds, tobacco settlement funds, or cigarette
taxes. In the case of Vermont and Maine, one compo-
nent of the assistance program is run through a Section
1115 Medicaid waiver; essentially a vehicle for a
discount program with no additional federal (or state)
money involved. (See glossary at the end of the paper
for a further explanation of the waiver.)
POLICY QUESTIONS
Several important policy questions for both federal
policymakers and state officials to consider include the
following:
 How would a federal Medicare prescription drug
benefit affect a state program and the beneficiaries
it serves? How are states planning for a transition,
so that beneficiaries maintain access to their medica-
tions? Would it be the intent of a federal benefit to
put a state program out of business?
 How would a federal Medicare prescription drug
benefit affect state Medicaid expenditures? Should
there be some trade-off of responsibilities if states
would see significant reductions in spending?
 If the debate in Congress over a Medicare prescrip-
tion drug benefit stalls or fails to result in a federal
solution, is it likely that states will continue on a
separate path?
 Could state-based assistance programs, if expanded,
be sufficient to cover those Medicare beneficiaries
without prescription drug coverage? (State programs
cover approximately 800,000 elderly/disabled per-
sons, but experts estimate that between six and nine
million Medicare beneficiaries “need” coverage based
on their income and health status.) What additional
program expansions might be needed? How should
they be structured? How should they be funded?
 When it comes to simplifying eligibility processes
and improving marketing and outreach, what lessons
can be drawn from states’ experiences with pro-
grams for women and children?
 What is the effect of various cost-sharing arrange-
ments on beneficiary enrollment?
 As states move beyond the more traditional state
pharmaceutical assistance programs and experiment
with more creative options, such as group purchas-
ing arrangements, price controls, and discount
programs (either as supplements to existing pro-
grams or as stand-alone options), how might these
new strategies play out over time?
 How should these state-based programs be evalu-
ated?
 What efforts are being (or should be) undertaken to
measure increased quality of care, better outcomes,
and decreased medication errors, as a result of the
establishment of these programs?
 What affect will the recent reimportation legislation,
(if implemented) have on state programs?
THE FORUM SESSION
Donna Folkemer, a program manager with the
National Conference of State Legislatures, will open the
session with an overview of state pharmaceutical
assistance programs. Folkemer, who specializes in
Medicaid, prescription drug, and disability issues at
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NCSL, will provide an inventory of state activity,
comparing and contrasting some of the older programs
with new approaches. Kevin W. Concannon, commis-
sioner of the Maine Department of Human Services,
will follow with a description of the activities that have
occurred in Maine. He will focus on the state’s older
pharmaceutical assistance plan, its waiver, its interaction
with Medicaid, and its first-of-a-kind “Maine Rx” law,
which seeks to control the price of prescription drugs.
To broaden the discussion, Katie B. Horton, R.N.,
J.D., president of HealthPolicy R&D, will present
alternative options for establishing state pharmaceutical
programs, and Joshua P. Cohen, Ph.D., a senior
research fellow with the Tufts Center for the Study of
Drug Development, will provide a marketplace scan,
reviewing the impact of these programs on pharmaceu-
tical manufacturers, chain drug stores, and pharmaceuti-
cal benefit managers. In addition, Cohen will discuss
the “big picture,” evaluating how well these assistance
programs reduce the prescription drug coverage gap.
GLOSSARY OF TECHNICAL TERMS
Drug Formulary—A list of prescription medications that
are preferred for use by a health plan and that may be
dispensed through participating pharmacies to covered
persons. This list is subject to periodic review and modifi-
cation by the health plan. A plan that has adopted an
“open or voluntary” formulary allows coverage of both
formulary and nonformulary medications. A plan that has
adopted a “closed, select or mandatory” formulary limits
coverage to those drugs in the formulary.6
Medicaid Rebates—The Omnibus Budget Reconcilia-
tion Act (OBRA) of 1990 established the Medicaid
rebate program. The basic formula requires that, in
exchange for having their product(s) reimbursed (that
is, included on the formulary), pharmaceutical manufac-
turers rebate to the states the greater of (a) 15.1 percent
of the average manufacturer price (AMP) paid by
wholesalers for brand-name drugs that Medicaid
beneficiaries purchase as outpatients or (b) the manufac-
turer’s “best price.” The best price is the lowest price
offered to any other customer, excluding Federal
Supply Schedule prices and prices to state pharmaceuti-
cal assistance programs. Similarly, manufacturers pay
a rebate equal to 11 percent of the AMP on generic and
over-the-counter drugs. The January 1996 Congressio-
nal Budget Office study, “How the Medicaid Rebate on
Prescription Drugs Affects Pricing in the Pharmaceuti-
cal Industry,” noted that
If a brand-name drug’s AMP increases faster than the
inflation rate, an additional rebate is imposed so that
manufacturers cannot offset the basic rebate by raising
their AMP. The additional rebate is equal to the
difference between the current AMP and a base-year
AMP increased by the inflation rate as measured by
the consumer price index.
Medicaid 1115 Waivers—Medicaid (Title XIX of the
Social Security Act) contains two types of waiver
authorities: program and demonstration. Program
waivers give states program flexibility in two specific
areas—alternative delivery and financing and home-
and community-based long-term care—while demon-
stration waivers offer opportunities for experimentation
and research.
Traditional Section 1115 waivers, while vehicles
allowing for significant departure from program rules,
are time-limited and subject to evaluation. An addi-
tional challenge to states considering Section 1115
waivers is the OMB regulation that they must be budget
neutral. Nevertheless, states have been using Section
1115 waivers to address the growing burdens of the
Medicaid populations. For example, Oregon has set
priorities on services and expanded its Medicaid base,
while Arizona has capitated its Medicaid population
and Hawaii has pooled its Medicaid beneficiaries and
uninsured residents into one managed care plan.7
The 1115 waiver that Vermont received8 for its
pharmaceutical assistance program is very different
from what is traditionally thought of as an 1115 waiver.
It is essentially a vehicle for a discount program with no
federal or state money involved. In Vermont, the
waiver, which is used in tandem with other elements of
Vermont’s prescription drug assistance program, works
as follows:
Medicare beneficiaries not eligible for Vermont’s
traditional subsidy program (up to 150% of poverty)
or any individuals with an income below 300% of
poverty and no drug coverage can sign up for the
Medicaid waiver program, called the Pharmacy
Discount Program. When an eligible person goes to
the drug store, she pays the price Medicaid would pay
for the drug minus the average Medicaid rebate
amount of about 15%. (This percentage would change
annually.) For example, for a drug that Medicaid pays
$100, the eligible individual would pay $85 as her
“co-pay”and the state would reimburse the pharmacist
the remaining $15 from the rebates it receives from
manufacturers. The beneficiary’s discount is reduced
by $3.00 for each of her first eight prescriptions to
cover an enrollment fee of $24 per person. The benefit
the enrollee receives varies by drug. A fact sheet from
Vermont, for example, indicates that Paxil costs
$77.89 retail and under the Vermont program, the
7 
1. Certain low-income Medicare beneficiaries (qualified
Medicare beneficiaries, or QMBs), receive assistance from
Medicaid for payment of Medicare cost-sharing charges, such
as premiums, deductibles, and coinsurance. These beneficia-
ries include the elderly with incomes below the federal
poverty line who are not Medicaid beneficiaries. In some
states, however, QMBs could be full Medicaid beneficiaries;
it depends on where the state sets its Medicaid income
eligibility limits. For Medicare beneficiaries with incomes
between 100 percent and 120 percent of poverty (specified
low-income Medicare beneficiaries, or SLMBs), Medicaid
pays only the Part B Medicare premium. Therefore, although
Medicaid will pay the coinsurance charges for the limited
outpatient drugs covered by Medicare (for QMBs), as well as
Part B premiums for both QMBs and SLMBs, most QMB-
onlys and SLMB-onlys do not have access to Medicaid’s
outpatient drug benefit.
2. U.S. General Accounting Office (GAO), State Pharmacy
Programs: Assistance Designed to Target Coverage and
Stretch Budgets (GAO/HEHS-00-162), September 2000, 4.
3. However, some of these programs (for example, Ne-
vada’s) that were scheduled to begin on January 1, 2001, have
not yet begun to provide benefits.
4. Much of this information is taken from the GAO Septem-
ber 2000 study and the National Conference of State Legisla-
tors’ Web site, http://www.ncsl.org.
5. For some discount-only programs, there are no limits.
6. National Pharmaceutical Council, Pharmaceutical Benefits
under State Medical Assistance Programs, December 1998.
7. Karen Matherlee, “Walking a Tightrope between Research
and Policy: The Medicaid and Medicare Waiver Processes,”
National Heath Policy Forum Issue Brief No. 632, Washing-
ton, D.C., October 29, 1993.
8. Maine also recently received a Section 1115 waiver that is
similar to Vermont’s. Maine’s waiver was approved in 10 days,
immediately before the administration changed. For a full
description, see State of Maine, “Maine Prescription Drug
Discount Waiver,” January 5, 2001; available at http://
janus.state.me.us/dhs/waiverreq.pdf.
9. Donna Folkemer, telephone conversation with author,
March 14, 2001.
10. For more detail, see Pharmaceutical Research and
Manufacturers of America, “Why HCFA’s New Waiver
Approval Violates the Medicaid Law”; available at http://
www.phrma.org/policy/statelevel/hcfa/.
enrollee pays $56.56 (the Medicaid price less the 15%
rebate.) This represents, for this particular drug, a
savings to the enrollee of about 27% off the retail
price.9
The Vermont waiver compels manufacturers to pay
rebates (since the program is run through Medicaid and
rebates are required by law in Medicaid), it holds the
prices of drugs to the Medicaid price, and the retail
pharmacists are “made whole” up to the Medicaid
payment level by the rebate payment they receive.
Under this waiver, neither the federal government nor
the state assumes any additional costs.
The Pharmaceutical Research and Manufacturers of
America (PhRMA) has filed a complaint against the
Health Care Financing Administration (HCFA) in the
U.S. District Court, stating that HCFA’s waiver ap-
proval violates federal Medicaid law.
The Secretary of the Department of Health and
Human Services [Shalala] and the state of Vermont
have, in effect, made an ‘end run’ around existing
federal law by creating a new ‘government’ program
with no government cost, but paid for solely by
private manufacturers. By doing so, the Secretary has
clearly exceeded her authority.10
Analysts have called this waiver approach “very
creative” and were surprised when HCFA approved this
type of waiver. Word about the waiver option has
gotten around fast and many states are considering this
approach. Some analysts are of the opinion that this is
the tip of the waiver iceberg, if it holds up in court.11
Medigap Rx Plans—Beneficiaries have purchased
supplemental insurance (referred to as Medigap poli-
cies) since the inception of the Medicare program as a
way to protect themselves against costs not covered by
the program (for example, outpatient prescription
drugs). Medigap insurance is specifically designed to
supplement Medicare’s benefits and is regulated by
federal and state law. Until the passage of OBRA 1990,
however, the Medigap market lacked standardization
among the benefits sold, creating confusion among
consumers. The Medigap provisions in OBRA 1990,
which became effective on July 30, 1992, required all
new Medigap policies to conform to one of ten stan-
dardized sets of benefits, or plans. These range from
Plan A, the basic benefit package, to Plan J, which
provides the greatest coverage.
Among other things, OBRA 1990 enabled beneficia-
ries to make informed choices about the benefits they
were purchasing. One of those benefits was outpatient
prescription drug benefits. Plans H, I, and J offer
prescription drug benefits. The costs of these plans are
high in comparison to other plans (in part, to compen-
sate for adverse risk selection), and the coverage is
quite limited.12
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11. Donna Folkemer, telephone conversation with author,
March 14, 2001.
12. Robin J. Strongin, “Providing Outpatient Prescription
Drugs through Medicare: Can We Afford To? Can We Afford
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Washington, D.C., March 1999.
